M32.0
Drug-induced systemic lupus erythematosus
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Medical Intelligence & Overview
Drug-induced systemic lupus erythematosus (SLE) is a condition that resembles the typical form of lupus but is specifically triggered by certain medications. Unlike classic lupus, which is an autoimmune disorder where the immune system attacks healthy tissues, drug-induced lupus develops as a side effect of specific drugs. Recognizing this condition is important because it often improves and resolves once the offending medication is discontinued. This overview will cover the causes, symptoms, diagnosis, and general approaches to managing drug-induced lupus.
Causes & Symptoms
Clinical Causes: Procainamide Hydralazine Isoniazid Methyldopa Quinidine Others, such as certain anti-seizure medications and biologic agents
Key Symptoms: Joint pain and swelling, particularly in the small joints of the hands and wrists Muscle pain Fever Fatigue and general feeling of being unwell Skin rashes, often similar to the butterfly rash seen in classic lupus Serositis, which involves inflammation of the lining around the lungs or heart Mild kidney or neurological involvement, usually less severe than in traditional lupus
Diagnostic & Treatment
Diagnosis Path: Reviewing the patient's medication history to identify potential triggering drugs Blood tests analyzing immune markers, such as antinuclear antibodies (ANA), which are often positive in lupus Assessing specific antibodies associated with lupus, like anti-histone antibodies, which tend to be elevated in drug-induced cases Excluding other causes of similar symptoms and ruling out idiopathic systemic lupus erythematosus Observation: Symptoms tend to improve or resolve after discontinuing the suspect medication
Treatment Protocols: Symptoms often improve within weeks to months Supportive treatments may include pain relievers, anti-inflammatory medications, or corticosteroids for symptomatic relief Regular follow-up with healthcare providers to monitor symptom resolution Alternative medications should be considered for conditions previously treated with the causative drugs Monitoring for potential flare-ups or atypical disease progression, though less common than idiopathic lupus
Clinical Advice & FAQs
Billing Guidance
Is M32.0 a billable ICD-10 code?
Yes, M32.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M32.0?
Clinical documentation must specify the nature of Drug-induced systemic lupus erythematosus and any associated comorbidities for accurate reporting.
Cite this Clinical Reference